2型糖尿病患者体重管理的研究进展与思考  

Weight management in type 2 diabetes mellitus:Recent advances and perspectives

作　　者：林毅 彭永德[1] Lin Yi;Peng Yongde(Department of Endocrinology and Metabolism,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai200080,China)

机构地区：[1]上海交通大学医学院附属第一人民医院内分泌代谢科,上海200080

出　　处：《中华内分泌代谢杂志》2024年第3期252-257,共6页Chinese Journal of Endocrinology and Metabolism

摘　　要：全球2型糖尿病患者人数仍在增加,其中肥胖问题不容忽视。肥胖不仅可能导致2型糖尿病的发生,也会进一步增加2型糖尿病患者的心血管疾病风险。因此,近年来2型糖尿病疾病管理的目标已经从控制血糖转变为"控糖、减重"双重管理。现有的减重策略包括生活方式干预、药物治疗和代谢手术,其中药物治疗的发展与日俱进。新型的双重或三重肠道激素受体激动剂的研发,将为2型糖尿病合并超重/肥胖患者提供更多治疗选择。The global pandemic of type 2 diabetes mellitus is still ongoing,in which obesity has played a major role.Obesity not only contributes to the development of type 2 diabetes but also further increases the risk of cardiovascular diseases in patients with type 2 diabetes.In recent years,the management goals of diabetes care has shifted from glycemic control alone to dual"glycemic control and weight loss".Current weight loss strategies include lifestyle intervention,pharmacotherapy therapy,and metabolic surgery,with advancements being made particularly in pharmacological treatments.The novel dual or triple gut hormone receptor agonists hold promise for providing more treatment options for overweight/obese patients with type 2 diabetes.

关 键 词：糖尿病 2型 体重 管理 多重靶点药物 

分 类 号：R587.1[医药卫生—内分泌]